CG Oncology, Inc. (NASDAQ:CGON) announced positive results from its Phase 3 BOND-003 trial for patients with high-risk non-muscle invasive bladder cancer. The study showed a complete response rate of 75.5% at any time, with 34 confirmed responses and nine patients still awaiting their 24-month assessment.
The trial demonstrated significant efficacy in patients who were unresponsive to Bacillus Calmette Guerin (BCG) treatment. Notably, 97.3% of patients remained free from progression to muscle-invasive disease after 24 months.
Additionally, Cohort P showed an estimated 90.5% high-grade recurrence-free survival at 3 and 9 months in 24 treated patients with BCG-unresponsive Ta/T1 disease without CIS. The safety profile was well-tolerated, with no Grade 3 or greater treatment-related adverse events reported.
The trial involved 110 highly pretreated patients, all of whom completed their expected treatments. CG Oncology’s stock price has surged 39.9% to $31.30 following the announcement.
Source: https://finance.yahoo.com/news/cg-oncologys-bladder-cancer-drug-151437058.html